CASE REPORT |
|
Year : 2012 | Volume
: 78
| Issue : 2 | Page : 175--177 |
Drug-induced hypersensitivity syndrome with human herpesvirus-6 reactivation
Najeeba Riyaz1, S Sarita1, G Arunkumar2, S Sabeena2, Neeraj Manikoth3, CP Sivakumar4
1 Department of Dermatology and Venereology, Government Medical College, Calicut, India 2 Manipal Centre for Virus Research (ICMR Virology Network Laboratory - Grade-I), Manipal University, Manipal, Karnataka State, India 3 Department of General Medicine, Government Medical College, Calicut, India 4 Department of Social and Preventive Medicine, Government Medical College, Calicut, India
Correspondence Address:
Najeeba Riyaz Arakkal, Chalapuram, Calicut - 673 002 India
 Source of Support: None, Conflict of Interest: None  | Check |
DOI: 10.4103/0378-6323.93635
A 45-year-old man, on carbamazepine for the past 3 months, was referred as a case of atypical measles. On examination, he had high-grade fever, generalized itchy rash, cough, vomiting and jaundice. A provisional diagnosis of drug hypersensitivity syndrome to carbamazepine was made with a differential diagnosis of viral exanthema with systemic complications. Laboratory investigations revealed leukocytosis with eosnophilia and elevated liver enzymes. Real-time multiplex polymerase chain reaction (PCR) on throat swab and blood was suggestive of human herpesvirus-6 (HHV-6). Measles was ruled out by PCR and serology. The diagnosis of drug-induced hypersensitivity syndrome (DIHS) was confirmed, which could explain all the features manifested by the patient. HHV-6 infects almost all humans by age 2 years. It infects and replicates in CD4 T lymphocytes and establishes latency in human peripheral blood monocytes or macrophages and early bone marrow progenitors. In DIHS, allergic reaction to the causative drug stimulates T cells, which leads to reactivation of the herpesvirus genome. DIHS is treated by withdrawal of the culprit drug and administration of systemic steroids. Our patient responded well to steroids and HHV-6 was negative on repeat real-time multiplex PCR at the end of treatment.
[FULL TEXT] [PDF]*
|